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Abstract
Background: Interferon-gamma (IFNg) is a multifunctional cytokine with antifibrotic and antiproliferative efficiency.
We previously found that pancreatic stellate cells (PSC), the main effector cells in cancer-associated fibrosis, are
targets of IFNg action in the pancreas. Applying a combined experimental and computational approach, we have
demonstrated a pivotal role of STAT1 in IFNg signaling in PSC. Using in vivo and in vitro models of pancreatic
cancer, we have now studied IFNg effects on the tumor cells themselves. We hypothesize that IFNg inhibits tumor
progression through two mechanisms, reduction of fibrogenesis and antiproliferative effects on the tumor cells. To
elucidate the molecular action of IFNg, we have established a mathematical model of STAT1 activation and
combined experimental studies with computer simulations.
Results: In BALB/c-nu/nu mice, flank tumors composed of DSL-6A/C1 pancreatic cancer cells and PSC grew faster
than pure DSL-6A/C1 cell tumors. IFNg inhibited the growth of both types of tumors to a similar degree. Since the
stroma reaction typically reduces the efficiency of therapeutic agents, these data suggested that IFNg may retain its
antitumor efficiency in PSC-containing tumors by targeting the stellate cells. Studies with cocultures of DSL-6A/C1
cells and PSC revealed a modest antiproliferative effect of IFNg under serum-free conditions. Immunoblot analysis
of STAT1 phosphorylation and confocal microscopy studies on the nuclear translocation of STAT1 in DSL-6A/C1
cells suggested that IFNg-induced activation of the transcription factor was weaker than in PSC. The mathematical
model not only reproduced the experimental data, but also underscored the conclusions drawn from the
experiments by indicating that a maximum of 1/500 of total STAT1 is located as phosphorylated STAT1 in the
nucleus upon IFNg treatment of the tumor cells.
Conclusions: IFNg is equally effective in DSL-6A/C1 tumors with and without stellate cells. While its action in the
presence of PSC may be explained by inhibition of fibrogenesis, its efficiency in PSC-free tumors is unlikely to be
caused by direct effects on the tumor cells alone but may involve inhibitory effects on local stroma cells as well.
To gain further insights, we also plan to apply computer simulations to the analysis of tumor growth in vivo.
Background
Accumulation of somatic mutations in genes regulating
cell growth, survival and differentiation represents a key
mechanism in the process of molecular carcinogenesis.
Over the last two decades, a large number of oncogenic
and anti-oncogenic signal transduction networks have
been described and generated considerable interest in
novel approaches aimed at a more systematic under-
standing of interactions between cellular proteins
involved in tumorigenesis. One strategy to meet this
goal is the introduction of mathematical models into
basic oncological research, taking advantage of recent
progress in the field of systems biology [1]. Most impor-
tantly, computational models are not only descriptive
but may also be used to make predictions that can be
tested experimentally. The growing value of systems
biology approaches in molecular research has raised
hopes that mathematical models may also be applied to
clinical oncology. To this day, however, there remains a
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related to subcellular processes) and the complexity of
tumor growth in vivo.
Here, we describe a pilot study designed to gain mole-
cular insights into the action of an antineoplastic agent
in pancreatic cancer (PC), a devastating disease with the
worst prognosis of all common human tumors [2,3].
O n eo ft h ek e yf e a t u r e so fP Ci st h ee x t e n d e df i b r o s i s ,
which has been linked to the activation of pancreatic
stellate cells (PSC) [4,5]. The desmoplastic reaction not
only accompanies the disease, but plays an active role in
its progression and reduces the efficiency of cytostatic
drugs [5-8]. We have previously shown that interferon-g
(IFNg) inhibits fibrogenesis by targeting PSC, and estab-
lished an ODE (ordinary differential equation)-model of
IFNg signaling through STAT1 (signal transducer and
activator of transcription) in PSC [9,10]. Simulations of
the parametric model not only reproduced experimental
data well, but also generated predictions regarding the
activation of the STAT1 pathway that could be experi-
mentally verified.
Interferons are multifunctional cytokines with anti-
viral, antiproliferative and immunomodulatory effects
[11]. Their antineoplastic action is exploited in the treat-
ment of several human malignancies. Thus, IFNa has
been proposed as an active component for the treatment
of PC as part of a chemoradiation protocol [12,13]. It is
currently unknown, however, which cells represent the
main targets of IFN action in vivo ( P Cc e l l s ,P S C ,o t h e r
cells?), and what are the molecular determinants of IFN
efficiency or inefficiency.
Using a mouse model of heterotopic PC, we initially
studied how IFNg affects the growth of tumor cells in the
presence and absence of co-injected PSC. Accompanying
in vitro studies were performed to determine the growth-
inhibitory effect of the cytokine on DSL-6A/C1 pancrea-
tic cancer cells and cocultures of tumor cells with PSC.
Furthermore, we analyzed IFNg signaling through
STAT1 in DSL-6A/C1 cells in a quantitative manner.
Subsequently, the signaling data were integrated into a
mathematical model of IFNg action in DSL-6A/C1 cells,
and linked to the results of our previous studies with stel-
late cells. Experimental and computational data together
suggest that the tumor cells are less responsive to IFNg
in that they require higher doses of the cytokine for effi-
cient STAT1 activation and growth inhibition. Interest-
ingly, IFNg nevertheless inhibited the growth of PSC-free
tumors in vivo, suggesting the existence of additional cel-
lular targets, such as local stroma cells.
Results
Effects of IFNg on PC growth in vivo and in vitro
To test the antitumor and antifibrotic efficiency of IFNg
in vivo, we established a mouse model of PC in which
the effects of the drug could be directly related to the
presence or absence of activated stellate cells. Therefore,
BALB/c-nu/nu mice (subsequently termed nude mice)
were injected with either DSL-6A/C1 pancreatic cancer
cells alone (one side), or a mixture of DSL-6A/C1 cells
and PSC (opposite flank). Systemic treatment with IFNg
was initiated when the faster-growing tumor had
reached a size of 6 mm in one dimension, and contin-
ued for 28 days. In accordance with published data [6],
tumors grew faster if PSC were co-injected (Figure 1).
As indicated by the tumor volumes, IFNg-treatment
d i m i n i s h e dt h eg r o w t hr a t eo fp u r eD S L - 6 A / C 1t u m o r s
in a non-significant manner (columns 5 and 6). On
PSC-containing tumors, IFNg displayed a quantitatively
similar, but statistically significant inhibitory effect (col-
umns 7 and 8). Based on these data, we hypothesized
that both stellate and cancer cells may be targets of
antiproliferative effects of IFNg. Expanding previous stu-
dies with cultured PSC, we therefore investigated the
antiproliferative effects of IFNg in a coculture model of
DSL-6A/C1 cells and PSC. In agreement with previous
studies [14], PSC stimulated the growth of the tumor
cells and vice versa (Figure 2 upper panel), although the
effect of stellate cells on DSL-6A/C1 cells just missed
statistical significance ( c o l u m n7 ;p=0 . 0 6 ) .I F N g at
100 ng/ml significantly inhibited the growth of both
types of cells under monoculture and coculture condi-
tions, providing evidence for the hypothesis described
above. However, the inhibitory effect of the cytokine on
the growth of DSL-6A/C1 cells was lost if the experi-
ment was performed in the presence of serum, or IFNg
concentration reduced to ≤ 10 ng/ml (Figure 2 middle
panel). In contrast, we have previously shown that pro-
liferation of PSC was significantly reduced by IFNg even
in the presence of FCS, and at a concentration as low as
1 ng/ml [9]. In order to gain mechanistic insights into
the cellular interactions, we analyzed the effect of the
coculture on PSC gene expression, focusing on a panel
of established PSC-derived mediators. As shown in
Figure 2 (lower panel), expression of connective tissue
growth factor (CTGF), transforming growth factor-b1
(TGF-b1) and interleukin (IL)-6 (but not IL-1) in PSC
was stimulated by cocultured tumor cells. The effects of
IFNg on PSC gene expression were altogether mild, with
a roughly two-fold up-regulation of IL-1b in cocultures
as the most pronounced phenomenon.
STAT1 pathway activation in DSL-6A/C1 cells: biological
data and mathematical model
The differences in the biological responsiveness of PSC
and DSL-6A/C1 cells to IFNg prompted us to ask if
they could be linked to different efficiencies of the cyto-
kine in the activation of the key transcription factor in
IFNg signaling, STAT1. To address the question, we
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tion in DSL-6A/C1 cells with computer simulations,
taking advantage of a previously established mathematical
model of STAT1 signaling in PSC [10]. The reaction net-
work used for computational analysis (Figure 3) contained
slight modifications of the previous one [10], which are
specified in the figure legend. Subsequently, the network
was translated into a system of ODEs, describing temporal
changes of the network components as a function of inter-
actions and transport processes. The parameters of the
model include reaction constants, delay times and the
total receptor concentration. Parameter estimation was
done by global optimization from protein and mRNA time
series for two different concentrations of IFNg (10 and
100 ng/ml). The ODEs and the optimized parameter
values are provided in the Additional files 1 and 2.
As shown in Figure 4 IFNg a tt h eh i g hd o s eo f1 0 0n g / m l
rapidly induced tyrosine phosphorylation of STAT1. Both,
a conventional visualization of the experimental data and
the application of the mathematical model concordantly
suggested that the increase of phospho-STAT1 happened
in two phases: An initial phase of rapid phosphorylation
was followed by a second phase characterized by a
slow but long-lasting further increase of phospho-STAT1
(Figure 5 upper left diagram). This second phase corre-
sponded to a rise of STAT1 protein levels (upper middle
diagram). Increased levels of phospho-STAT1 and STAT1
protein were synchronously detectable in the cytosolic and
nuclear cell fraction (middle and lower row, respectively),
and well reproduced by the mathematical model. Accord-
ingly, the STAT1 target gene suppressor of cytokine signal-
ing (SOCS1) also displayed a biphasic pattern of enhanced
expression (middle row, right diagram).
A quantitative analysis of confocal microscopy data
(see Figure 6 for a typical example) and computational
simulation together (Figure 5 upper row, right diagram)
revealed the surprising finding that IFNg-induced phos-
phorylation of STAT1 left the ratio of nuclear to cyto-
plasmic STAT1 almost unchanged. We therefore
hypothesize that only a small fraction of cytoplasmic
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Figure 1 Growth rates of PSC-containing and PSC-free DSL-6A/C1 tumors in nude mice and effects of IFNg. Injections of tumor cells,
alone or together with PSC, was performed as described in the “Methods” section. Treatment with IFNg (10 μg per day for 4 weeks, n = 4)
started when the faster-growing tumor had reached a size of 6 mm in one dimension (day 0). Initiation of IFNg treatment is indicated by the
symbol (+). Control animals (n = 6) received solvent injections only. Indicated are the average values of the tumor volumes ± SEM. * p < 0.05 vs.
without PSC (paired t-test), # p < 0.05 vs. untreated (unpaired t-test).
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Figure 2 Effects of IFNg on the DNA synthesis and gene expression. Upper panel: DSL-6A/C1 cells and PSC were either cultured alone
(columns 1, 2, 5 and 6) or together (columns 3, 4, 7 and 8) in transwell plates. After IFNg treatment for 48 h under serum-free conditions as
indicated, proliferation of DSL-6A/C1 cells (columns 1-4) and PSC (columns 5-8) was assessed with the BrdU incorporation assay. One hundred
percent cell proliferation corresponds to DSL-6A/C1 cells or PSC cultured alone and without IFNg. Data from 12 separate cultures were used to
calculate mean values and SEM. * p < 0.05 vs. untreated monocultures, # p < 0.05 versus untreated cocultures (Wilcoxon’s rank sum test). Middle
panel: DSL-6A/C1 cells were cultured with or without FCS and IFNg as indicated for 24 h, before DNA synthesis was assessed with the BrdU
incorporation assay. One hundred percent BrdU incorporation corresponds to controls cultured without IFNg. Data are presented as mean ± SEM
(n = 6 separate cultures); * p < 0.05 vs. control cultures (Wilcoxon’s rank sum test). Lower panel: Monocultures of PSC and cocultures of PSC with
DSL-6A/C1 cells were treated with IFNg at 100 ng/ml for 24 h. The mRNA expression of CTGF, TGF-b1, IL-6, IL-1b and the housekeeping gene
HPRT in PSC was analyzed by real-time PCR, and relative amounts of target mRNA were calculated as described in the “Methods” section. One
hundred percent mRNA expression of each gene (dotted line) corresponds to PSC monocultures grown without IFNg. Data of 3 independent
experiments (with triplicate samples) were used to calculate mean values and SEM.
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after IFNg stimulation. Direct evidence in support of
this hypothesis comes from parameter estimation of the
mathematical model: According to these results a rela-
tive concentration of 1/500 of total STAT1 is an upper
boundary for the concentration of phosphorylated
STAT1 in the nucleus. This is presented in detail in the
Additional file 3.
We also tested the effects of a lower dose of IFNg,
10 ng/ml, on STAT1 activation (Figure 7). Both, visualiza-
tion of experimental data and computational simulations
of the mathematical model showed that dose reduction
resulted in a slower rise of phospho-STAT1 levels (upper
panel), while the enhanced expression of STAT1 protein
at later time points after IFNg application was retained
(lower panel). At 1 ng/ml, IFNg did not activate STAT1 at
all (data not shown). Together, these results suggest that
the antiproliferative effect of IFNg in DSL-6A/C1 cells is
closely related to the activation of STAT1.
Discussion
Integrating the design of experiments with mathematical
modeling is considered a promising approach to unravel
the molecular complexity of tumors [1]. Although com-
putational models may be applied to various fields of
cancer research, an improved mechanistic understanding
cytoplasm
STAT1Uc
time delay
time delay
nucleus SOCS1
STAT1Dn
STAT1Dc
plasma
membrane
IFNJ
Ir IIr
STAT1Uc
STAT1Un
Delayed inhibition 
of phosphorylation STAT1Dnd
Figure 3 Reaction network of the IFNg stimulated STAT1 signaling pathway. The network shows key reactions of the pathway, which are
translated into a mathematical model. IFNg activates the receptor Ir. To keep the model simple, Janus kinases are not considered separately but
as part of the active receptor complex IIr only. IIr phosphorylates unphosphorylated cytosolic STAT1 (STAT1Uc), followed by rapid formation of
homodimers (STAT1Dc). STAT1Dc translocates into the nucleus (STAT1Dn) and induces the transcription of specific target genes by binding to
the DNA (STAT1Dnd). When dimerized nuclear STAT1 is not bound to the DNA, dimers may dissociate, followed by protein dephosphorylation
and nuclear export of the resulting STAT1Un [27]. STAT1Uc can also shuttle into the nucleus [32]. The network considers SOCS1 as a potential
negative feedback regulator inhibiting the phosphorylation of STAT1Uc [28,29] and STAT1 itself as target genes of IFNg-activated signaling [10].
The annotation time delay refers to temporal differences between IFNg action at the receptor level and consecutive steps. The level of
phosphorylated STAT1 did not decrease despite induction of SOCS1 expression (Fig. 5). This observation suggests that the negative feedback
could be effective at late times (≥ 180 min) only, where it could reduce the slope of the late increase of phosphorylated STAT1. In comparison
to the network previously established for stellate cells [10], only two reactions were changed: Since the experimental data showed no decrease
of STAT1 phosphorylation, IFNg degradation and receptor deactivation were neglected.
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least at the current stage. Here, we have analyzed the
biological and molecular effects of IFNg in rat pancreatic
cancer cells, using a combined experimental and com-
putational approach. Our studies were motivated by the
following considerations:
Interferons are of clinical interest in the treatment of
pancreatic cancer [12,13]. Moreover, they display antifi-
brotic effects in different tissues [9,15,16], suggesting that
they may enhance direct antitumor action by inhibiting
pancreatic fibrosis; a progression factor of the disease.
We have previously shown that pancreatic stellate cells,
the main effector cells in fibrosis, are highly susceptible
to IFNg treatment [9], and developed a mathematical
model of IFNg signaling through STAT1 [10], the princi-
pal transcription factor in the mediation of IFNg effects
[17,18]. By expanding experimental and modeling efforts
to tumor cells, we expected new insights regarding the
relative sensitivity of both cell types to the drug.
In contrast to stellate cells [9,19], DSL-6A/C1 cells did
not respond to IFNg by diminished cell proliferation as
long as they were cultured in the presence of serum.
A reduced rate of DNA synthesis was only observed
when IFNg was applied at the high dose of 100 ng/ml,
and combined with another stressor, the withdrawal of
serum. To obtain a detectable STAT1 phosphorylation
in DSL-6A/C1 cells, an IFNg concentration ≥ 10 ng/ml
was required, while in cultured stellate cells 1 ng/ml
was sufficient [10]. Furthermore, the activation profile of
STAT1 in DSL-6A/C1 cells differed from the one pre-
viously observed in stellate cells in that a reduction of
cytokine concentrations from 100 to 10 ng/ml was asso-
ciated with a slower increase of phospho-STAT1 (Figure
8). As revealed by parameter value optimization of the
mathematical model, a maximum of 1/500 of total
STAT1 is located as phosphorylated STAT1 in the
nucleus upon IFNg treatment of DSL-6A/C1 cells.
Together, these results indicate that the cancer cells are
less sensitive towards IFNg than pancreatic stellate cells,
and suggest a less efficient activation of STAT1 signal-
ing as a possible molecular explanation.
In the nude mouse model, it was found that PSC-
containing tumors grew faster and to larger volumes than
pure DSL-6A/C1 tumors. This finding is in agreement
with previous studies, which have revealed that co-injected
PSC accelerate the growth of pancreatic cancer in animal
models of the disease [6,20,21]. Moreover, the tumor
stroma in pancreatic cancer has been shown to induce
resistance of the tumor cells to drug treatment [7,8,22].
Possible mechanisms include paracrine effects of the
stroma cells, an inefficient delivery of the antineoplastic
agent to the tumor tissue, and a protection of the tumor
against the immune system of the host (less relevant in
the immunodeficient nude mouse model). In this context,
it was interesting to note that IFNg inhibited the growth of
tumors with and without stellate cells in a similar manner.
When grown in coculture, both PSC and DSL-6A/C1
cells proliferated at a higher rate than monocultures of
the respective cell type, confirming previous results [14].
The antiproliferative effect of IFNg on both types of
cells, however, remained significant, suggesting that its
efficiency was not affected by the paracrine interactions
between tumor and stellate cells. Molecular coupling
factors between PSC and DSL-6A/C1 factors may
include CTGF, TGF-b1a n dI L - 6 ,a l lo fw h i c hw e r e
found to be up-regulated in PSC upon coculture, and
are known to be involved in PSC activation [5]. In the
coculture model, IFNg increased expression of IL-1b,
which might favor the development of a pro-inflamma-
tory microenvironment in the tumor.
The sensitivity of pure DSL-6A/C1 tumors towards
IFNg treatment warrants further investigation. In pilot
STAT1P D 91 kDa
STAT1P E 84 kDa
STAT1 D 91 kDa
STAT1 E 84 kDa
ERK 1 44 kDa
ERK 2 42 kDa
60 600 240 30 720 360 120 0 20 10 480 0 180 5 IFNJ (min)
Figure 4 Time course of phospho-STAT1 and STAT1 protein levels in IFNg-stimulated DSL-6A/C1 cells. The cells were stimulated under
serum-free conditions with IFNg (100 ng/ml) for up to 720 min. Total cellular lysates from an equal number of cells were subjected to
immunoblot analysis. Primary antibodies were detected with the help of fluorescein (IRDye
®)-labeled secondary antibodies. Phospho-STAT1
(STAT1P), STAT1 protein and ERK 1/2 staining are exemplarily shown for one blot. The samples were loaded in a randomized order to exclude
lane correlated blotting errors caused by gel and transfer inhomogeneities, as previously suggested [33].
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fibroblasts to the tumor, where they may exert effects of
tumor stroma cells and are possibly targeted by IFNg.
It has to be noted that the antitumor efficiency of
IFNg may also depend on the differentiation status of
the pancreatic cancer cells: IFNg-responsive DSL-6A/C1
tumors are relatively well differentiated. Purely differen-
tiated tumors of Panc02 cells [22], however, were found
to be resistant to IFNg treatment when growing in
C57Bl/6N mice (R. Jaster, unpublished data).
To this end, we have used the systems biology
approach for the in vitro part of our experiments only.
Nevertheless, modeling and simulation proved helpful
since it provided additional mechanistic insights into the
action of IFNg, which was the focus of this study. We
are currently extending the effort to the simulation of
experimental tumor growth in vivo. We believe that in
the long run modeling may also become a valuable tool
to monitor and predict the efficiency of antineoplastic
agents. A major challenge on this way is the lack of
quantitative and kinetic data of high density and quality,
appropriate for data-driven modeling in which para-
meter values of kinetic (dynamical) models are directly
estimated from time course data.
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Figure 5 IFNg-induced STAT1 pathway activation: Experimental time series and computational simulation results. Experimental data:
DSL-6A/C1 cells were stimulated with IFNg at 100 ng/ml for the indicated periods of time. Experimentally determined levels of phospho-STAT1,
total STAT1 protein (immunoblot data received from total cellular lysates, the cytosolic cell fraction and the nuclei, respectively) and SOCS1
mRNA were normalized as described in the “Methods section”. They are expressed in arbitrary units (a.u.) as averaged values of four to six
independent experiments (± SEM). The immunoblot and PCR time series were scaled according to the requirements of the optimization
methods. Confocal microscopy data were processed by calculating the ratio of nuclear versus cytoplasmic STAT1 concentration. The data are
averaged values (± SEM) of 30 to 40 cells from three to four different images for each time point. Measured data are presented by blue symbols
with error bars. Computational simulations: The simulated time courses resulting from the mathematical model with optimized parameters for
STAT1, nuclear translocation of STAT1, STAT1P and SOCS1 mRNA are presented by solid red lines.
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In a heterotopic nude mouse model of pancreatic can-
cer, IFNg significantly inhibited the growth of tumors
containing co-transplanted stellate cells, which acceler-
ated tumor progression. On pure DSL-6A/C1 tumors,
IFNg displayed a quantitatively similar but statistically
not significant growth inhibitory effect. PSC are more
sensitive to the antiproliferative action of IFNg than
DSL-6A/C1 pancreatic cancer cells. A possible explanation
is provided by our experimental data and computer simu-
lations, since they concordantly indicate that in DSL-6A/
C1 cells only a small fraction of the key transcription fac-
tor STAT1 is located as phosphorylated protein in the
nucleus upon IFNg stimulation. We therefore hypothesize
06 0 IFNJ (min)
Staining:
STAT1
Nuclei
Merged
Figure 6 Immunocytochemical analysis of total STAT1 expression and subcellular localisation. DSL-6A/C1 cells treated with IFNg (100 ng/
ml) as indicated were stained by incubation with specific antibodies detecting STAT1. Upper row: Binding of primary antibody was visualized
with an Alexa Fluor
® 488-labeled secondary antibody, resulting in green fluorescence. Middle row: Nuclei were counterstained with TO-PRO
®-3
iodide (shown in red color). Lower row: merged pictures. Microphotographs were analyzed by confocal laser scanning microscopy (original
magnification × 400).
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C1 tumors is mediated, at least in part, by the targeting of
additional cell types, such as local fibroblasts.
Methods
Materials
Iscove’s modified Dulbecco’s medium (IMDM), Dul-
becco’s Modified Eagle Medium (DMEM) and supple-
ments for cell culture were obtained from Biochrom
(Berlin, Germany), recombinant rat IFNg from Immu-
notools (Friesoythe, Germany), and bovine serum albu-
min (BSA) from Roche Diagnostics (Mannheim,
Germany). TriReagent
® was purchased from Ambion
(Austin, TX, USA). Reverse transcription and Taq-
man
™ reagents were delivered by Applied Biosystems
(Foster City, CA, USA). Primary antibodies were from
BD Biosciences (Franklin Lakes, NJ, USA; anti-pY701-
STAT1; mouse monoclonal), Upstate Cell Signaling
Solutions (Billerica, MA, USA; anti-extracellular signal-
regulated kinase (ERK) 1/2; rabbit polyclonal), Santa
Cruz (Santa Cruz, CA, USA; anti-STAT1; rabbit poly-
clonal) and New England BioLabs (Frankfurt, Ger-
many; anti-GAPDH; rabbit monoclonal and anti-lamin
A/C; rabbit polyclonal). Fluorescently-labeled second-
ary antibodies for immunoblot analysis and Odyssey
®
blocking buffer were supplied by LI-COR (Lincoln, NE,
USA). Polyvinylidene fluoride (PVDF) membrane was
from Millipore (Billerica, MA, USA), and TO-PRO
®-3
iodide as well as Alexa Fluor
® reagents from Invitro-
gen (Darmstadt, Germany). Tissue culture dishes
(corning plasticware) and all other chemicals were
from Sigma (Deisenhofen, Germany).
Cell culture
Stellate cells from rat pancreas were isolated by collage-
nase digestion of the organ followed by Nycodenz den-
sity gradient centrifugation as previously described [23],
and cultured in IMDM supplemented with 17% fetal
calf serum (FCS), 1% non-essential amino acids (dilution
of a 100 × stock solution), 100 U/ml penicillin and
100 μg/ml streptomycin. PSC were harvested by trypsi-
nization on day seven after isolation and recultured at
equal seeding densities according to the experimental
requirements. All experiments were performed with
cells passaged no more than 2 times. The rat pancreas
carcinoma cell line DSL-6A/C1 was obtained from
American Type Culture Collection (ATCC), and cul-
tured in DMEM supplemented with 10% FCS and anti-
biotics (100 U/ml penicillin; 100 μg/ml streptomycin).
Coculture studies were performed in 24-transwell
plates using inserts with a pore size of 0.4 μm. There-
fore, DSL-6A/C1 cells and PSC were seeded into the
upper or lower chamber of separate transwells, respec-
tively. After an overnight incubation, culture medium
was replenished, transwell chambers were assembled by
transferring the inserts, and IFNg was added according
to the experimental design. All cells were grown at 37°C
in a 5% CO2 humidified atmosphere.
Animal tumor model and IFNg treatment
BALB/c-nu/nu mice were purchased from Charles River
Laboratories (Sulzfeld, Germany), kept under standard
laboratory conditions and fed a rodent chow diet.
All experiments were performed according to the guide-
lines of the local animal use and care committee.
T h r e em o n t ho l dm a l em i c ew e r ei n j e c t e ds u b c u t a -
neously into the left hind flank with 1×10
6 DSL-6A/C1
cells, and a mixture of 1×10
6 DSL-6A/C1 cells/1×10
6
PSC into the opposite site. Over the entire period of
investigation, tumor growth was monitored twice a
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Figure 7 Effects of IFNg at 10 ng/ml on STAT1 protein
expression and phosphorylation. Experimental data: DSL-6A/C1
cells were stimulated with IFNg for the indicated periods of time.
Phospho-STAT1 and STAT1 protein levels in total cellular lysates
were determined by immunoblot analysis. The data were processed
as described in the legend to Fig. 5. Averaged values (± SEM) of
four independent experiments are presented by blue symbols.
Computational simulations: The simulated time courses resulting
from the mathematical model are presented by solid red lines.
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Page 9 of 13week, and volumes of outgrowing tumors were evaluated
according to the following formula: width
2 ×l e n g t h×
0.52 [24]. Treatment was initiated when the faster-
growing tumor had reached a size of 6 mm in one
dimension (defined as day 0). Therefore, the mice were
randomized into two groups, and treated with IFNg
(intraperitoneal injections of 10 μg per day, n = 4), or sol-
vent only (controls; n = 6) for 28 days. Afterwards, the
animals were sacrificed, and tumors from both flanks
removed for further analysis.
Cell proliferation assay
To assess proliferation of cells growing alone or in
coculture, incorporation of 5-bromo-2’-deoxyuridine
(BrdU) into newly synthesized DNA was quantified
using the BrdU labeling and detection enzyme-linked
immunosorbent assay kit (Roche Diagnostics). There-
fore, the cells were incubated with IFNg and BrdU as
indicated, and BrdU uptake of cells growing in the
lower chamber (PSC and DSL-6A/C1 cells, respectively)
was measured according to the manufacturer’si n s t r u c -
tions. In studies with monocultures of DSL-6A/C1 or
PSC, transwell inserts were omitted. For each experi-
mental regime (coculture studies, dose-response experi-
m e n t sa n ds t u d i e so nt h ee f f e c t so fF C S ) ,t h et i m e so f
IFNg treatment were optimized in pilot investigations.
Immunoblotting
To receive unfractionated total cellular protein, boiling
lysis buffer (2% sodium dodecyl sulphate [SDS], 10% gly-
cerol, 5 mM ethylenediaminetetraacetic acid [pH 8.0],
62.5 mM Tris-HCl [pH 6.8], 0.01% 3,3’,5,5’-tetrabromo-
phenolsulfonphthalein, 5% b-mercaptoethanol) was
added directly to the cell monolayer. Nuclear extracts
and the cytosolic fraction of the cells were prepared
using the ProteoJET
™ cytoplasmic and nuclear protein
extraction kit (Fermentas, St. Leon-Rot, Germany)
according to the instructions of the manufacturer.
Cellular proteins received from equal numbers of cells
were separated by 8% SDS-polyacrylamide gel electro-
phoresis and blotted onto PVDF membrane. Afterwards,
membranes were blocked for one hour using Odyssey
®
blocking buffer, before primary antibodies were added
and incubation continued for another hour. Simulta-
neous detection of tyrosine-phosphorylated STAT1 and
total STAT1 was performed as previously described
[10]. Expression of ERK 1/2, GAPDH and lamin A/C
was investigated by adding specific antibodies separately
to the lower part of the membrane. IRDye
® 800CW and
IRDye
® 680CW conjugated secondary antibodies were
applied for detection of primary antibody binding.
Using an Odyssey
® Infrared Imaging System, all
immunoblots were scanned at a wavelength of 700 nm
for detecting IRDye
® 680 labeled antibodies and at a
wavelength of 800 nm for IRDye
® 800CW conjugated
antibodies. Signal intensities were quantified by means
of the Odyssey
® software version 3.16. Signals obtained
for phosphorylated STAT1 and total STAT1 protein
were normalized for loading differences by calculating
the ratio of phospho-STAT1 (or STAT1) to ERK 1/2
(total cellular protein), GAPDH (cytosolic fraction) and
lamin A/C (nuclear extracts). Under the experimental
conditions used in this study, protein levels of ERK 1/2,
GAPDH and lamin A/C in the cells remained constant
(data not shown). In a second step each time series was
normalized to its average value over time. Finally the
average value of four to six experiments was calculated
for each time point.
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Figure 8 Phosphorylation profiles of total STAT1 in DSL-6A/C1 cells and stellate cells treated with IFNg at 10 ng/ml. Shown are the data
and computational simulations of this investigation (DSL-6A/C1 cells) and our previous study with stellate cells [10].
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DSL-6A/C1 cells were cultured on coverslips. After sti-
mulation with IFNg, the cells were fixed in methanol at
-20°C for 10 min and washed twice with TBS (20 mM
Tris, 150 mM NaCl, pH 7.6; supplemented with 0.5%
BSA, 0.05% Tween20). Nonspecific binding sites were
blocked with Roti
®-ImmunoBlock solution (Carl Roth,
Karlsruhe, Germany). Afterwards, the fixed cells were
incubated with anti-STAT1 (in Roti
®-ImmunoBlock
solution) overnight at 4°C. After washing with TBS, the
coverslips were stained with Alexa Fluor
® 488 goat anti-
rabbit IgG. Subsequently, the cells were washed and
nuclei were stained with TO-PRO
®-3 iodide. Finally, the
cells were fixed with 2% paraformaldehyde for 15 min
and embedded in mounting medium (25% glycerol, 10%
polyvinylalcohol, 0.4% phenol, 0.05 M Tris, pH 8.5) on
microscope slides. Fluorescence analysis was performed
by using a confocal laser scanning microscope LSM 5
Pascal (Axiovert 200 M) and Zen 2007 (4.5) software
(Carl-Zeiss, Jena, Germany). Images were further ana-
lyzed using the ImageJ (Open Source software package).
To quantify nuclear translocation of STAT1, averaged
ratios of nuclear versus cytoplasmic concentration (sum
of pixel intensity divided by area) of STAT1 were calcu-
lated. Therefore, 30 to 40 cells from three to four differ-
ent images were analyzed for each time point.
Quantitative reverse transcriptase-PCR using real-time
TaqMan
™ technology
DSL-6A/C1 cells and PSC, growing in FCS-containing cul-
ture medium, were treated with IFNg as indicated, and
total RNA was isolated with TriReagent
® according to the
manufacturer’s instructions. Subsequently, RNA was
reverse transcribed into cDNA by means of TaqMan
™
Reverse Transcription Reagents and random hexamer
priming. Target cDNA levels were analyzed by quantita-
tive real-time PCR using TaqMan™ Universal PCR
Master Mix and the following Assay-on-Demand
™ rat
gene-specific fluorescently labelled TaqMan™ MGB
probes in an ABI Prism 7000 sequence detection system
(Applied Biosystems): Rn00595838_s1 (SOCS1),
Rn00573960_g1 (CTGF), Rn00580432_m1 (IL-1b),
Rn00561420_m1 (IL-6), Rn00572010_m1 (TGF-b1) and
Rn01527840_m1 (hypoxanthine-guanine phosphoribosyl
transferase [HPRT]). PCR was started with an initial dena-
turation at 95°C for 10 min, followed by 55 cycles of 15 s
at 95°C and 1 min at 60°C. The relative expression of each
mRNA compared with HPRT was calculated according to
the equation ΔCt = Cttarget -C t HPRT. After averaging over
at least two technical replicates, the amount of target
m R N Aw a se x p r e s s e da s2
-(ΔCt).I nc a s eo ft i m ec o u r s e
experiments, the time series of 2
-(ΔCt) was normalized to
its average value over time. Finally, the averaged value of
the indicated number of experiments was calculated for
each time point.
Mathematical model
The reaction network (Figure 3), describing IFNg signal-
ing in DSL-6A/C1, was translated into a system of ODEs
which describe temporal changes of the network compo-
nents as a function of interactions and transport pro-
cesses. The model is presented in the Additional file 1.
The kinetic model is based on the following assump-
tions and simplifications: (a) There is no IFNg degrada-
tion. (b) IFNg activates Ir and the active receptor IIr
phosphorylates STAT1U. (c) The formation of STAT1
D is a rapid and high affinity process [25,26].
(d) Nucleo-cytoplasmic shuttling is modeled as a free
diffusion process. (e) The quantification of the confocal
microscopy data led to the result that the cytoplasmic
area occupied by STAT1 has the same size as the
nuclear area (data not shown). (f) Our model includes a
r e v e r s i b l eb i n d i n go fS T A T 1Dt oD N A ,w h i c hd e t e r -
mines the resting of STAT1 D in the nucleus [27],
( g )O n l yf r e en u c l e a rS T A T 1Dc a nb ed e p h o s p h o r y -
lated and dissociate into monomers, leading to nuclear
STAT1U [26]. (h) Feedback inhibition by SOCS1 may
reduce STAT1U phosphorylation [28,29]. (i) The
delayed processes of increased STAT1U expression,
SOCS1 transcription and the negative feedback by
SOCS1 are described by a distributed time delay with
mean delay times  i[30]. The model assumptions are
the same as for our model in PSC except of (a) and (b).
For further details regarding the assumptions see [10].
Parameter value estimation
The parameters of the model whose values need to be
estimated include reaction constants, delay times, immu-
noblot scaling factors and initial conditions of some
model variables. Their values are estimated by global
optimization from protein and mRNA time series for
low concentrations (10 ng/ml) and higher concentra-
tions (100 ng/ml) of IFNg. For estimation we have used
a hybrid approach combined of a stochastic simulated
annealing algorithm performing a global search and a
deterministic trust region algorithm performing a local
search. The hybrid approach is implemented in the rou-
tine pwFitBoost of the MATLAB toolbox PottersWheel
[31]. Results from parameter value estimation are pre-
sented in the Additional files 2 and 3.
Statistical analysis
Results are expressed as means ± standard error of the
mean (SEM) for the indicated number of animals or
independent cultures per experimental protocol. Statisti-
cal significance was determined using tests as specified
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as statistically significant.
Additional material
Additional file 1: Mathematical model describing the reactions of
the network in Figure 3. The reaction network was translated into a
system of ordinary differential equations (ODE), which describes temporal
changes of the network components as a function of interactions and
transport processes. The ODE model is shown in the upper part of
Additional file 1. The abbreviation S stands for STAT1. The variables of
the model representing cellular components are concentrations but their
units are arbitrary due to the lack of standard curves. The initial
conditions of IIr, STAT1Dn and STAT1Dnd were set to zero. They are
summarized below the ODE. The initial condition of a variable refers to
its value at time point zero and is annotated by (0) after its name. The
total concentration of STAT1 and the total IFNg receptor concentration I
are redundant parameters. We have fixed I as 1/10 of initial experimental
STAT1. The initial value of STAT1 results from the optimization of the
initial values of STAT1Dc, STAT1Uc and STAT1Un. The algebraic equations
in the lower part of Additional file 1 relate the model variables to the
experimental data. Immunoblot data can be scaled by arbitrary factors.
We have chosen different scaling factors for STAT1c, STAT1n, STAT1 D,
STAT1Dc, STAT1Dn, annotated by “WB” with the respective form of the
protein in the subscript. Scaling factors for STAT1 and SOCS1 mRNA have
not been included because scaled variables inserted in the model show
that the respective scaling factors are redundant parameters. In addition,
the ratio of nuclear versus cytoplasmic concentration of STAT1 (RSNC)
has been calculated from the confocal microscopy data.
Additional file 2: Estimation of parameter values.
a While global
parameters are independent of the IFNg concentration, local parameters
depend on it. a.u. = arbitrary units. The parameters of the mathematical
model include reaction constants and delay times. The parameter values
were estimated by global optimization from the protein and mRNA time
series. We have used a hybrid algorithm composed of simulated
annealing and a local search implemented in the MATLAB toolbox
PottersWheel [1]. As a measure for the goodness of how a simulation of
the model reproduces experimental data, the following cost function
was applied:
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where θ is the parameter vector, ykl
exp are the experimental data,
yk
mod values of observables at time points of the experimental
data  kl
exp and is the measurement error of the experimental data
[1].References1. Maiwald T, Timmer J: Dynamical modeling and
multi-experiment fitting with PottersWheel. Bioinformatics 2008,
24:2037-2043.
Additional file 3: Cost function for different fixed relative
concentrations of STAT1Dn for IFNg = 100 ng/ml. To estimate an
upper boundary for the relative concentration of nuclear STAT1Dn, we
fixed the scaling factor WBSTAT1Dn at different increasing values and re-
optimized the other parameter values. The respective values of the cost
function are summarized in the left part of the table. For WBSTAT1Dn =
1000 the cost function reaches a plateau. In the right part of the table
the maximal relative concentration of STAT1Dn is calculated from this
value. For t = 180 min the concentration of STAT1Dn is 1/500 of the
STAT1 concentration and for t = 720 min the concentration of STAT1Dn
is 1/1000 of STAT1 concentration.
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a.u.: arbitrary unit; ATCC: American Type Culture Collection; BrdU: 5-bromo-
2’-deoxyuridine; BSA: bovine serum albumine; CTGF: connective tissue
growth factor; DMEM: Dulbecco’s Modified Eagle Medium; ERK: extracellular
signal-regulated kinase; FCS: fetal calf serum; HPRT: hypoxanthine-guanine
phosphoribosyl transferase; IFN: interferon; IMDM: Iscove’s modified
Dulbecco’s medium; IIr: active IFNγ receptor; IL: Interleukin; Ir: inactive IFNγ
receptor; PC: pancreatic cancer; PSC: pancreatic stellate cell; PVDF:
polivinylidene fluoride; ODE: ordinary differential equation; RSNC: ratio of
nuclear versus cytoplasmic concentration of STAT1; SDS: sodium dodecyl
sulphate; SEM: standard error of the mean; SOCS: suppressor of cytokine
signaling; STAT: signal transducer and activator of transcription; STAT1P:
phosphorylated (Phospho-) STAT1; STAT1c: STAT1 in the cytoplasm; STAT1n:
STAT1 in the nucleus; STAT1D: phosphorylated STAT1 dimer; STAT1Dc:
phosphorylated STAT1 dimer in the cytoplasm; STAT1Dn: phosphorylated
STAT1 dimer in the nucleus; STAT1Dnd: phosphorylated STAT1 dimer bound
to DNA; STAT1U: unphosphorylated STAT1; STAT1Uc: unphosphorylated
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